Dolutegravir — Discount Pricing

Other medications in Infections

• Doripenem
• Efavirenz
• Emtricitabine
• Entecavir
• Ertapenem
• Erythromycin
• Ethambutol
• Famciclovir

About Dolutegravir

Dolutegravir is a vital antiretroviral medication used to treat HIV-1 infection in adults and children. As a cornerstone of many treatment regimens, access and affordability are crucial. TheDrugClub is dedicated to helping members manage their prescription costs, offering opportunities for significant savings on medications like dolutegravir.

Dolutegravir is an antiretroviral drug specifically approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It can be used in combination with other antiretroviral agents for both treatment-naive and treatment-experienced adults and adolescents, as well as in children weighing at least 30 kg. It helps to reduce the viral load and improve the immune system, allowing individuals living with HIV to lead healthier, longer lives.

How Dolutegravir Works

Dolutegravir belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs). It works by blocking HIV integrase, an enzyme that HIV needs to multiply. Specifically, integrase is responsible for integrating the viral DNA into the DNA of human cells. By inhibiting this crucial step, dolutegravir prevents the virus from replicating and spreading, effectively reducing the amount of HIV in the body and protecting immune

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dolutegravir is approved for (FDA label)

TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 12.4 )]. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.

Source: Read the full FDA label on DailyMed. Label effective date: May 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dolutegravir (FDA label)

TIVICAY Tablets: 10 mg: Each tablet contains 10 mg of dolutegravir (as dolutegravir sodium). Tablets are white, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “10” on the other side. 25 mg: Each tablet contains 25 mg of dolutegravir (as dolutegravir sodium). Tablets are pale yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “25” on the other side. 50 mg: Each tablet contains 50 mg of dolutegravir (as dolutegravir sodium). Tablets are yellow, round, film-coated, biconvex tablets debossed with “SV 572” on one side and “50” on the other side. TIVICAY PD Tablets for Oral Suspension: Each tablet contains 5 mg of dolutegravir (as dolutegravir sodium).

Source: FDA prescribing information (DailyMed). Set ID: 485bc9db-8665-9f5a-e063-6394a90a7921. SPL document ID: 526982bc-f7b7-0c37-e063-6394a90a6d6f. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dolutegravir (FDA label)

The following serious adverse drug reactions are discussed in other sections of the labeling: Hypersensitivity reactions [see Warnings and Precautions ( 5.1 )] . Hepatotoxicity [see Warnings and Precautions ( 5.2 )]. Immune Reconstitution Syndrome [see Warnings and Precautions ( 5.4 )] . The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are insomnia, fatigue, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 485bc9db-8665-9f5a-e063-6394a90a7921. SPL document ID: 526982bc-f7b7-0c37-e063-6394a90a6d6f. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dolutegravir (FDA label)

TIVICAY and TIVICAY PD are contraindicated in patients: with previous hypersensitivity reaction to dolutegravir [see Warnings and Precautions ( 5.1 )]. receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see Drug Interactions ( 7 )] . Previous hypersensitivity reaction to dolutegravir. ( 4 ) Coadministration with dofetilide. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 485bc9db-8665-9f5a-e063-6394a90a7921. SPL document ID: 526982bc-f7b7-0c37-e063-6394a90a6d6f. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dolutegravir (FDA label)

Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported. Discontinue TIVICAY or TIVICAY PD and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. ( 5.1 ) Hepatotoxicity has been reported in patients receiving dolutegravir-containing regimens. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations. Monitoring for hepatotoxicity is recommended. ( 5.2 ) Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. ( 5.4 ) TIVICAY tablets and TIVICAY PD tablets for oral suspension are not substitutable. ( 2.2 , 5.5 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.

Source: FDA prescribing information (DailyMed). Set ID: 485bc9db-8665-9f5a-e063-6394a90a7921. SPL document ID: 526982bc-f7b7-0c37-e063-6394a90a6d6f. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dolutegravir (FDA label)

Refer to the full prescribing information for important drug interactions with TIVICAY or TIVICAY PD. ( 4 , 7 ) Drugs that are metabolic inducers may decrease the plasma concentrations of dolutegravir. ( 7.2 , 7.3 ) TIVICAY or TIVICAY PD should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. When taken with food, TIVICAY and supplements containing calcium or iron can be taken at the same time. ( 7.3 ) 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE) 1 (IC 50 = 6.34 microM).

Source: FDA prescribing information (DailyMed). Set ID: 485bc9db-8665-9f5a-e063-6394a90a7921. SPL document ID: 526982bc-f7b7-0c37-e063-6394a90a6d6f. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.